A nitric oxide synthase inhibitor
Ki: 3.0 μM for nNOS; 10.0 μM for eNOS; 9.5 μM for iNOS
Methyl-L-NIO is a competitive nitric oxide synthase (NOS) inhibitor.
Nitric oxide synthase (NOS) catalyzes the NADPH- and O2-dependent conversion of L-arginine to nitric oxide (NO). Three isoforms, the neuronal (nNOS), endothelial, and inducible, have been identified. Since NO overproduction contributes to various pathophysiological conditions, NOS inhibitors are considered as potential therapeutic agents.
In vitro: Previous study found that both methyl-L-NIO and its close analog ethyl-L-NIO were more potent inhibitors of nNOS than of eNOS or iNOS. However, expressed on a Ki/Km basis, neither of these two inhibitors showed biologically significant selectivity for nNOS over eNOS. In fact, both compounds showed a very modest selectivity for iNOS over the constitutive isoforms. In addition, methyl-L-NIO required a 10-fold higher concentration to duplicate the inactivation seen with L-NIO. Further extension to form the saturated analog of L-VNIO such as ethyl-L-NIO led to an inactivation of nNOS under the conditions examined [1].
In vivo: Up to now, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Babu, B.?R., and Griffith, O.W. N5-(1-Imino-3-butenyl)-L-ornithine. A neuronal isoform selective mechanism-based inactivator of nitric oxide synthase. The Journal of Biological Chemisty 273, 8882-8889 (1998).
动态评分
0.0